VBLT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VBLT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Vascular Biogenics has an F-score of 5 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Vascular Biogenics's Piotroski F-Score or its related term are showing as below:
During the past 11 years, the highest Piotroski F-Score of Vascular Biogenics was 5. The lowest was 2. And the median was 3.
The historical data trend for Vascular Biogenics's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vascular Biogenics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Piotroski F-Score | Get a 7-Day Free Trial | 2.00 | 4.00 | 2.00 | 3.00 | 4.00 |
Vascular Biogenics Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Piotroski F-Score | Get a 7-Day Free Trial | 3.00 | 3.00 | 4.00 | 3.00 | 5.00 |
For the Biotechnology subindustry, Vascular Biogenics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vascular Biogenics's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Vascular Biogenics's Piotroski F-Score falls into.
How is the Piotroski F-Score calculated?
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Jun23) TTM: | Last Year (Jun22) TTM: |
Net Income was -9.17 + -3.272 + -2.639 + -0.874 = $-15.96 Mil. Cash Flow from Operations was -6.821 + -6.721 + -1.688 + -2.362 = $-17.59 Mil. Revenue was 0.481 + 0 + 0 + 0 = $0.48 Mil. Gross Profit was 0.418 + 0.048 + -0.002 + 0 = $0.46 Mil. Average Total Assets from the begining of this year (Jun22) to the end of this year (Jun23) was (45.319 + 35.526 + 29.659 + 28.113 + 24.646) / 5 = $32.6526 Mil. Total Assets at the begining of this year (Jun22) was $45.32 Mil. Long-Term Debt & Capital Lease Obligation was $0.00 Mil. Total Current Assets was $24.55 Mil. Total Current Liabilities was $5.30 Mil. |
Net Income was -6.502 + -9.107 + -10.428 + -9.434 = $-35.47 Mil. Revenue was 0.199 + 0.196 + 0.113 + 0.064 = $0.57 Mil. Gross Profit was 0.108 + 0.101 + 0.058 + 0.03 = $0.30 Mil. Average Total Assets from the begining of last year (Jun21) to the end of last year (Jun22) was (67.34 + 61.14 + 64.661 + 56.289 + 45.319) / 5 = $58.9498 Mil. Total Assets at the begining of last year (Jun21) was $67.34 Mil. Long-Term Debt & Capital Lease Obligation was $1.39 Mil. Total Current Assets was $35.69 Mil. Total Current Liabilities was $8.81 Mil. |
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Vascular Biogenics's current Net Income (TTM) was -15.96.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Vascular Biogenics's current Cash Flow from Operations (TTM) was -17.59.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Score 1 if it's higher, 0 if it's lower.
ROA (This Year) | = | Net Income | / | Total Assets (Jun22) |
= | -15.955 | / | 45.319 | |
= | -0.35205984 |
ROA (Last Year) | = | Net Income | / | Total Assets (Jun21) |
= | -35.471 | / | 67.34 | |
= | -0.52674488 |
Vascular Biogenics's return on assets of this year was -0.35205984. Vascular Biogenics's return on assets of last year was -0.52674488.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Score 1 if CFROA > ROA, 0 if CFROA <= ROA.
Vascular Biogenics's current Net Income (TTM) was -15.96. Vascular Biogenics's current Cash Flow from Operations (TTM) was -17.59.
==> -17.59 <= -15.96 ==> CFROA <= ROA ==> Score 0.
Funding
Question 5. Change in Gearing or Leverage
Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.
Score 0 if this year's gearing is higher, 1 otherwise.
Gearing (This Year: Jun23) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Jun22 to Jun23 |
= | 0 | / | 32.6526 | |
= | 0 |
Gearing (Last Year: Jun22) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Jun21 to Jun22 |
= | 1.389 | / | 58.9498 | |
= | 0.02356242 |
Vascular Biogenics's gearing of this year was 0. Vascular Biogenics's gearing of last year was 0.02356242.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Current Ratio (This Year: Jun23) | = | Total Current Assets | / | Total Current Liabilities |
= | 24.548 | / | 5.301 | |
= | 4.63082437 |
Current Ratio (Last Year: Jun22) | = | Total Current Assets | / | Total Current Liabilities |
= | 35.688 | / | 8.809 | |
= | 4.05131116 |
Vascular Biogenics's current ratio of this year was 4.63082437. Vascular Biogenics's current ratio of last year was 4.05131116.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Vascular Biogenics's number of shares in issue this year was 78.394. Vascular Biogenics's number of shares in issue last year was 77.399.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Gross Margin (This Year: TTM) | = | Gross Profit | / | Revenue |
= | 0.464 | / | 0.481 | |
= | 0.96465696 |
Gross Margin (Last Year: TTM) | = | Gross Profit | / | Revenue |
= | 0.297 | / | 0.572 | |
= | 0.51923077 |
Vascular Biogenics's gross margin of this year was 0.96465696. Vascular Biogenics's gross margin of last year was 0.51923077.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Asset Turnover (This Year) | = | Revenue | / | Total Assets at the Beginning of This Year (Jun22) |
= | 0.481 | / | 45.319 | |
= | 0.01061365 |
Asset Turnover (Last Year) | = | Revenue | / | Total Assets at the Beginning of Last Year (Jun21) |
= | 0.572 | / | 67.34 | |
= | 0.00849421 |
Vascular Biogenics's asset turnover of this year was 0.01061365. Vascular Biogenics's asset turnover of last year was 0.00849421.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score | = | Que. 1 | + | Que. 2 | + | Que. 3 | + | Que. 4 | + | Que. 5 | + | Que. 6 | + | Que. 7 | + | Que. 8 | + | Que. 9 |
= | 0 | + | 0 | + | 1 | + | 0 | + | 1 | + | 1 | + | 0 | + | 1 | + | 1 | |
= | 5 |
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Vascular Biogenics has an F-score of 5 indicating the company's financial situation is typical for a stable company.
Vascular Biogenics (NAS:VBLT) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Thank you for viewing the detailed overview of Vascular Biogenics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Builders Vc Fund I, L.p. | 10 percent owner | 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105 |
James Jimin Kim | 10 percent owner | C/O NOTABLE LABS, INC., 320 HATCH DRIVE, FOSTER CITY CA 94404 |
B Capital Group Management, L.p. | 10 percent owner | 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266 |
B Capital Group Investors Ii Ltd. | 10 percent owner | 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266 |
B Capital Group Partners Ii, L.p. | 10 percent owner | 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266 |
Joseph P Wagner | officer: Chief Scientific Officer | 320 HATCH DRIVE, FOSTER CITY CA 94404 |
Tuomo Patsi | director | 320 HATCH DRIVE, FOSTER CITY NY 94404 |
Thomas Bock | director, officer: Chief Executive Officer | 320 HATCH DRIVE, FOSTER CITY NY 94404 |
Michele Galen | director | 320 HATCH DRIVE, FOSTER CITY CA 94404 |
Fr Capital Holdings, L.p. | 10 percent owner | 2400 MARKET STREET, SUITE 237, PHILADELPHIA PA 19103 |
B Capital Fund Ii, L.p. | 10 percent owner | C/O B CAPITAL GROUP MANAGEMENT, L.P., 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266 |
Builders Vc Fund I (canada), L.p. | 10 percent owner | 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105 |
Builders Vc Entrepreneurs Fund I, L.p. | 10 percent owner | 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105 |
Dubin Thomas I H | director | C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Peter Feinberg | director | C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-29-2022
By GuruFocusNews GuruFocusNews • 07-10-2022
By sperokesalga sperokesalga • 05-15-2023
By Business Wire • 08-28-2023
By sperokesalga sperokesalga • 02-26-2023
By PRNewswire • 08-29-2023
By GuruFocusNews GuruFocusNews • 07-09-2022
By PurpleRose PurpleRose • 07-19-2022
By Value_Insider Value_Insider • 11-14-2022
By Marketwired • 10-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.